According to www.techsciresearch.com latest Report- Favipiravir is an anti-viral medication, which is a pyrazine carboxamide derivative, Asia Pacific favipiravir market is expected to grow at an impressive rate during the forecast period. The Asia Pacific favipiravir market is driven by the extensive use of this drug in the treatment of COVID-19 disease Report URL- https://www.techsciresearch.com/report/asia-pacific-favipiravir-market/4719.html

1. MARKET INTELLIGENCE . CONSULTING
www.techsciresearch.com
ASIA PACIFIC FAVIPIRAVIR MARKET
FORECAST & OPPORTUNITIES
2015 – 2025

2. 2
Scope of Report
Product of Interest (POI): Favipiravir
si
Review Period
2015 – 2019
Base Year
2019
Estimated Year
2020
Forecast Period
2021 – 2025
Year Range
DOSAGE FORM
COUNTRY
• China
• India
• Australia
• Japan
• South Korea
• Pakistan
• Thailand
• Singapore
• Vietnam
• Malaysia
• Bangladesh
• Tablet
• Capsule
Asia Pacific favipiravir market is expected to grow at an impressive rate during the forecast period. The Asia Pacific
favipiravir market is driven by the extensive use of this drug in the treatment of COVID-19 disease as it has similar
mechanism of action against the COVID-19 virus it has against the influenza virus. The drug inhibits the activity of
RNA polymerase and COVID-19 is unable to replicate. Additionally, the clinical trials are going on in the U.S., Italy and
Japan and as of now it is believed that the drug could come out as a potential treatment for COVID-19. This is
expected to positively influence the market growth during forecast period.
Market Segmentation
• Hospitals
• Clinics
• Drug
Stores/Pharmacies
• Online
• Others
DISTRIBUTION
CHANNEL
• Oral
• Intravenous
ROUTE OF
ADMINISTRATION
• Influenza A&B
• Ebola
• COVID-19
APPLICATION

3. 3
Table of Contents
S.No
. Contents
1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on Asia Pacific Favipiravir Market
4. Executive Summary
5. Asia Pacific Favipiravir Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Oral v/s Intravenous)
5.2.2. By Dosage Form (Tablet v/s Capsule)
5.2.3. By Distribution Channel (Hospitals, Clinics, Drug Stores/Pharmacies, Online, Others)
5.2.4. By Application (Influenza A&B, Ebola, COVID-19)
5.2.5. By Country (China, India, Australia, Japan, South Korea, Pakistan, Thailand, Singapore,
Vietnam, Malaysia, Bangladesh)
5.2.6. By Company (2019)
5.3. Product Market Map
6. China Favipiravir Market Outlook
6.1. Market Size & Forecast

4. 4
Table of Contents
Contents
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Route of Administration
6.2.2. By Dosage Form
6.2.3. By Distribution Channel
6.2.4. By Application
6.2.5. By Company
6.3. Competition Outlook
7. India Favipiravir Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. By Dosage Form
7.2.3. By Distribution Channel
7.2.4. By Application
7.2.5. By Company
7.3. Competition Outlook
8. Australia Favipiravir Market Outlook
8.1. Market Size & Forecast

5. 5
Table of Contents
Contents
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Route of Administration
8.2.2. By Dosage Form
8.2.3. By Distribution Channel
8.2.4. By Application
8.2.5. By Company
8.3. Competition Outlook
9. Japan Favipiravir Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Route of Administration
9.2.2. By Dosage Form
9.2.3. By Distribution Channel
9.2.4. By Application
9.2.5. By Company
9.3. Competition Outlook
10. South Korea Favipiravir Market Outlook
10.1. Market Size & Forecast

6. 6
Table of Contents
Contents
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Route of Administration
10.2.2. By Dosage Form
10.2.3. By Distribution Channel
10.2.4. By Application
10.2.5. By Company
10.3. Competition Outlook
11. Pakistan Favipiravir Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value & Volume
11.2. Market Share & Forecast
11.2.1. By Route of Administration
11.2.2. By Dosage Form
11.2.3. By Distribution Channel
11.2.4. By Application
11.2.5. By Company
11.3. Competition Outlook
12. Thailand Favipiravir Market Outlook
12.1. Market Size & Forecast

7. 7
Table of Contents
Contents
12.1.1. By Value & Volume
12.2. Market Share & Forecast
12.2.1. By Route of Administration
12.2.2. By Dosage Form
12.2.3. By Distribution Channel
12.2.4. By Application
12.2.5. By Company
12.3. Competition Outlook
13. Singapore Favipiravir Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value & Volume
13.2. Market Share & Forecast
13.2.1. By Route of Administration
13.2.2. By Dosage Form
13.2.3. By Distribution Channel
13.2.4. By Application
13.2.5. By Company
13.3. Competition Outlook
14. Vietnam Favipiravir Market Outlook
14.1. Market Size & Forecast

8. 8
Table of Contents
Contents
14.1.1. By Value & Volume
14.2. Market Share & Forecast
14.2.1. By Route of Administration
14.2.2. By Dosage Form
14.2.3. By Distribution Channel
14.2.4. By Application
14.2.5. By Company
14.3. Competition Outlook
15. Malaysia Favipiravir Market Outlook
15.1. Market Size & Forecast
15.1.1. By Value & Volume
15.2. Market Share & Forecast
15.2.1. By Route of Administration
15.2.2. By Dosage Form
15.2.3. By Distribution Channel
15.2.4. By Application
15.2.5. By Company
15.3. Competition Outlook
16. Bangladesh Favipiravir Market Outlook
16.1. Market Size & Forecast

9. 9
Table of Contents
Contents
16.1.1. By Value & Volume
16.2. Market Share & Forecast
16.2.1. By Route of Administration
16.2.2. By Dosage Form
16.2.3. By Distribution Channel
16.2.4. By Application
16.2.5. By Company
16.3. Competition Outlook
17. Market Dynamics
17.1. Drivers
17.2. Challenges
18. Market Trends & Developments
18. Pricing Analysis
18. Patent Analysis
19. Competitive Landscape
20. Strategic Recommendations
21. About Us & Disclaimer

10. RESEARCHMETHODOLOGY

11. 11
Research Methodology
✓ Identifying Key Opinion
Leaders
✓ Questionnaire Design
✓ In-depth Interviews
Data
Collection
Developing List
of Respondents
Formulating
Questionnaire
Market
Profiling
Data
Validation
Data
Analysis
In-depth secondary
research was conducted to
determine top players in
the Asia Pacific favipiravir
market, overall market size
and segmental market size.
In order to conduct
industry experts’
interviews, TechSci
formulated a detailed
discussion guide.
List of industry
players and industry
specialists was
developed.
TechSci conducted
interviews with
industry experts and
industry players for
data collection and
verification.
Data obtained as a
result of primary
and secondary
research was
validated through
rigorous
triangulation.
The data was scrutinized
using MS-Excel, statistical
tools and internal
proprietary database to
obtain qualitative and
quantitative insights about
the Asia Pacific favipiravir
market.
Data
Collection
Data Filter
& Analysis
Research &
Intelligence
Actionable
Insights
Business
Solution
Primary Research Desk Research CompanyAnalysis
✓ Recent Developments
✓ Market Changing
Aspects/Dynamics
✓ Government Policies
✓ Conclusion
✓ Market Participants
✓ Key Strengths
✓ LinkedIn
✓ TechSci Internal
Database
✓ Factiva
✓ Hoovers
Paid Sources
✓ Company Websites
✓ Company Annual
Reports
✓ White Paper Study
✓ Financial Reports
✓ Investor
Presentations
✓ Regulatory Body
✓ Associations, etc.
Secondary
Research
Primary Research

12. 12
Research Methodology
Baseline Methodology
Our dedicated team of industry experts has monitored and analyzed various aspects of Asia Pacific favipiravir market. The team has analyzed the
outlook of various segments of this market, while considering the major influencing factors such as extensive use of this drug in the treatment of
COVID-19 disease. The study includes market forecasting, which would enable our clients to take better decisions while planning their strategy to
achieve sustainability in this market.
Methodology Followed for Calculation of Market Size:
• Market Size by: Market size, in terms of value and volume, for the year 2019 was calculated based on information collected through exhaustive
secondary research and primary surveys, with various key opinion leaders/stakeholders, such as favipiravir companies, channel partners, market
influencers & end users, industry experts, and other industry participants.
• The team interviewed more than 15 – 20 favipiravir companies, 45 – 50 channel partners, 80 – 100 end users, and 15 – 20 industry experts and other
value chain stakeholders in the Asia Pacific favipiravir market to obtain the overall market size from 2015 to 2019, which was validated by the Delphi
technique. Taking standard deviation into consideration, the market size was averaged out, to arrive at the market size data during 2015-2019.

13. 13
Research Methodology
• Respondents were asked about the current and future market growth rates, market shares by route of administration, by dosage form, by
distribution channel, by application, by country and by company. Removing the outlier responses, the geometric mean of growth estimates and
supplier wise revenue shares generated across various segments were considered, to arrive at the final revenue shares. Revenue shares generated
across various segments were further triangulated from other stakeholders.
• Methodology Followed for Calculation of Market Shares:
Market shares by route of administration, by dosage form, by distribution channel, by application, by country and by company were calculated based
on the responses received through primary surveys with industry experts, in which the respondents were asked about the market shares or revenue
generated from various segments of favipiravir market. The final shares were calculated by taking the geometric mean of the responses gathered from
key opinion leaders after eliminating the outliers.
Methodology Followed for Forecasting:
• TechSci Research performed periodical checks on data collected through the surveys with logic checks and analyzed the survey results in
SPSS/Tableau Software.
• Data triangulation techniques were applied to fill the gaps and to present a more meaningful picture of the market to forecast Asia Pacific favipiravir
market, TechSci Research used various forecast techniques such as:
✓ Moving Average
✓ Time Series Analysis
✓ Regression Analysis
✓ Econometric and Judgmental Analysis

14. 14
Research Methodology
TechSci Research used its own forecast tool, which is based on the growth of various allied industries in respective regions. TechSci Research also used
the impact analysis during short, medium- and long-term period to estimate the demand and to reach accurate market numbers. It should be noted
that the figures compiled are only for the organized market including market share data. The currency used in the report is the United States Dollar
(USD), with the market size indicated in USD million.
Partial List of Companies Interviewed Key Secondary Sources
▪ Fujifilm Toyoma Chemicals Co. Ltd.
▪ Zhejiang Hisun Pharmaceuticals
▪ Cipla
▪ Shouyuan Chemical
▪ Hunan Huateng Pharmaceuticals Co. Ltd.
▪ Lasa Supergenerics Ltd.
▪ Beximco
▪ Beacon Pharmaceuticals
▪ Sihuan Pharmaceuticals
▪ World Bank
▪ TechSci Research Proprietary Database &
Knowledge Repository
▪ Company Annual Reports
▪ Industry Magazines
▪ Industry Reports
▪ News Dailies
▪ Credible Paid Databases

15. 15
Industry Brief
According to TechSci Research report, “Asia Pacific Favipiravir Market By Route of Administration (Oral v/s Intravenous), By Dosage Form (Tablet v/s Capsule), By Distribution Channel (Hospitals,
Clinics, Drug Stores/Pharmacies, Online, Others), By Application (Influenza A&B, Ebola, COVID-19), By Country, Forecast & Opportunities, 2025”, the Asia Pacific favipiravir market is expected to
grow at an impressive rate during the forecast period on account of the growing use of the drug in treating various diseases such as influenza, ebola, among others. Additionally, growing use of the
drug in treatment of COVID-19, which at present has no approved drug or treatment, is expected to positively influence the market growth. Furthermore, the drug is already in the phase 3 of clinical
trials and might emerge out as a potential coronavirus treatment drug. This is expected to create lucrative opportunities for the market growth. Also, it has been observed that the drug is helpful in
reducing the recovery duration from 11 days to 4 days among mild & regular COVID-19 positive tested cases. However, this is an antiviral drug, which is approved for the treatment of influenza and
has no approval or clinical evidence for treating COVID-19 disease. It is just being used as no harmful effects have been observed so far. Besides, availability of other drugs and generics might
hinder the market growth across the globe. Furthermore, this drug should not be given to pregnant women as it can affect the fetal development process. This in turn is expected to negatively impact
the market growth through 2025.
The Asia Pacific favipiravir market is segmented based on route of administration, dosage form, distribution channel, application, company and region. Based on dosage form, the market can be
divided into tablet and capsule. The tablets segment is expected to dominate the market since they are inexpensive, safe and effective in delivering oral medication. On the other hand, the capsules
segment is expected to hold a significant market share on account of quick relief they offer. They breakdown quickly as compared to the tablets. Additionally, they have higher bioavailability, as a
result of which, more of a drug is likely to enter the bloodstream. Also, they are tasteless, hence do not leave any unpleasant taste or odor. Based on application, the market can be fragmented into
influenza A&B, ebola and COVID-19. The influenza segment is expected to dominate the market since the drug is primarily used for the treatment of influenza and has the approval for that from the
FDA. On the other hand, COVID-19 segment is expected to register significant growth until 2025 on account of the increasing use of this drug for treating COVID-19 struck patients.
Fujifilm Toyoma Chemicals Co. Ltd., Zhejiang Hisun Pharmaceuticals, Cipla, Shouyuan Chemical, Hunan Huateng Pharmaceuticals Co. Ltd., Lasa Supergenerics Ltd., Beximco, Beacon
Pharmaceuticals, Sihuan Pharmaceuticals and others are some of the leading players operating in Asia Pacific favipiravir market.
“Asia Pacific favipiravir market is expected to witness significant growth during the forecast period on account of the increasing prevalence of COVID-19 in the region, which at present, is incurable.
Additionally, the drug has entered phase 3 clinical trials and Fujifilm Toyoma is quite confident that the drug will get approval for the treatment of COVID-19. Furthermore, use of this drug by various
countries such as Italy, U.S., among others, is anticipated to create lucrative opportunities for the market growth over next few years.” said Mr. Karan Chechi, Research Director with TechSci
Research, a research based global management consulting firm.

16. 16
Sample Data - Snapshot
Asia Pacific Favipiravir Market Size, By Value (USD Million), By Volume (Million), 2015–2025F
5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
10.00 20.00 30.00 40.00 50.00 60.00 70.00 80.00 90.00 100.00 110.00
2015 2019 2020E 2025F
By Value (USD Million)
By Volume (Million)
CAGR By Value & Volume
XX%
CAGR By Value & Volume
YY%
Asia Pacific Favipiravir Market Share, By Route of Administration, By Value, 2015–2025F
50% 50% 50% 50% 50% 50% 50% 50% 50% 50% 50%
50% 50% 50% 50% 50% 50% 50% 50% 50% 50% 50%
2015 2016 2017 2018 2019 2020E 2021F 2022F 2023F 2024F 2025F
Oral
Intravenous
China Favipiravir Market Share, By Application, By Value, 2015–2025F
33% 33% 33% 33% 33% 33% 33% 33% 33% 33% 33%
33% 33% 33% 33% 33% 33% 33% 33% 33% 33% 33%
34% 34% 34% 34% 34% 34% 34% 34% 34% 34% 34%
2015 2016 2017 2018 2019 2020E 2021F 2022F 2023F 2024F 2025F
Influenza
A&B
Ebola
COVID-19

17. 17
Report Ordering
License Type Price
Electronic Access - Single User License $3950
Electronic Access - Multi-User License $4950
Custom Research License $8950
Report Price
To View Sample OR Purchase Report
Report Name: ASIA PACIFIC FAVIPIRAVIR MARKET
FORECAST & OPPORTUNITIES
2015 – 2025

18. About Us & Disclaimer
TechSci Research is a global market research and consulting company with offices in the US, UK and China. TechSci Research provides market research reports in number of
areas to organizations. The company uses innovative business models that focus on improving productivity, while ensuring creation of high-quality reports. The proprietary
forecasting models use various analyses of both industry-specific and macroeconomic variables on a state-by-state basis to produce a unique ‘bottom-up’ model of a country,
regional and global industry prospects. Combined with the detailed analysis of company activity and industry trends, the result is a uniquely rich evaluation of the opportunities
available in the market.
Related Reports
• India Dexamethasone Market By Type (Injectables, Capsules, Tablets, Solutions), By Route of Administration (Oral v/s Intravenous), By Application
(Asthma, Rheumatoid Arthritis, Skin Disorders, Covid-19, Ulcerative Colitis, Lupus, Allergic Disorders, Psoriasis, Others), By End Users (Hospitals,
Clinics, Pharmacy, Others), By Region, Forecast & Opportunities, FY2026
• Global Hydroxychloroquine and Chloroquine Market By Type (Injectables & Tablets), By Route of Administration (Oral v/s Intravenous), By Strength
(100mg, 250mg & 500mg), By Application (Rheumatoid Arthritis, Malaria, COVID-19, Others), By Region, Competition, Forecast & Opportunities,
2030
The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely, accurate or
complete. TechSci Research has taken due care and caution in compilation of data as this has been obtained from various sources including which it considers reliable and firsthand.
However, TechSci Research does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible for any errors or omissions or for the results
obtained from the use of such information and especially states that it has no financial liability whatsoever to the subscribers / users of this report. The information herein, together
with all estimates and forecasts, can change without notice. All the figures provided in this document are indicative of relative market size and are strictly for client’s internal
consumption. Usage of the same for purpose other than internal will require prior approval of TechSci Research.
TechSci Research – North America
708 Third Avenue, Manhattan,
New York, United States
Tel: +1- 646- 360- 1656
Email: sales@techsciresearch.com
www.techsciresearch.com
Disclaimer
TechSci Research – Europe
54, Old brook, Bretton,
Peterborough,
United Kingdom
Email: sales@techsciresearch.com
www.techsciresearch.com
TechSci Research – SE Asia-Pacific
B – 44, Sector – 57, Noida, National Capital
Region, U.P. - China
Tel: +91-120-4523900
Email: sales@techsciresearch.com
www.techsciresearch.com